

Drug Safety Updates

SFDA Approved Risk Management Measures (RMMs)

The summary view in the table includes reviewed and approved Risk minimization measures by SFDA:

Product	Measure
Rivaroxaban QO® (Rivaroxaban)	HCP Guide Arabic Patient Card English Patient Card
Hemgenix® (Etranacogene Dezaparvovec)	HCP Guide Arabic Patient Card English Patient Card Arabic Patient Guide English Patient Guide
Polivy® (POLATUZUMAB VEDOTIN)	DHPC
Keroz® (Fingolimod)	HCP Checklist English Patient Card Arabic Patient Card
Fenido® (Pirfenidone)	HCP Checklist
Victoza®, Saxenda®, Evonanz®, Zelyssa®, Ligma® (Liraglutide)	DHPC
Ozempic®, Tasylev®, Wegovy®, Rybelsus® (Semaglutide)	DHPC
SOLIQUA SOLOSTAR® (Lixisenatide)	DHPC
Mounjaro® (Tirzepatide)	DHPC
Trulicity® (Dulaglutide)	DHPC
Gemorya® (Fingolimod Hydrochloride)	HCP Checklist Arabic Patient Guide English Patient Guide
Zapnex® (Clozapine)	HCP Guide English Patient Card Arabic Patient Card

**Measures: additional minimization activities that should be done by the marketing authorization holder to minimize the risk.*